FRISCO, Texas--(BUSINESS WIRE)--Oct. 24, 2013--
Greatbatch, Inc. (NYSE:GB), today announced results for its third
quarter ended September 27, 2013 highlighted by 5% constant currency
organic revenue growth, 18% improvement in adjusted operating income and
24% improvement in adjusted diluted EPS over the prior year.
|
|
Three Months Ended
|
(Dollars in thousands, except per share data)
|
|
September 27,
|
|
September 28,
|
|
%
|
|
June 28,
|
|
%
|
|
2013
|
|
2012
|
|
Change
|
|
2013
|
|
Change
|
Sales
|
|
$
|
167,730
|
|
|
$
|
161,340
|
|
|
4
|
%
|
|
$
|
171,331
|
|
|
-2
|
%
|
Constant Currency Organic Sales Growth
|
|
|
5
|
%
|
|
|
8
|
%
|
|
|
|
|
|
6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Operating Income
|
|
$
|
17,002
|
|
|
$
|
2,127
|
|
|
NA
|
|
|
$
|
17,135
|
|
|
-1
|
%
|
GAAP Operating Income as % of Sales
|
|
|
10.1
|
%
|
|
|
1.3
|
%
|
|
|
|
|
|
10.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Operating Income*
|
|
$
|
22,012
|
|
|
$
|
18,664
|
|
|
18
|
%
|
|
$
|
22,192
|
|
|
-1
|
%
|
Adjusted Operating Income as % of Sales
|
|
|
13.1
|
%
|
|
|
11.6
|
%
|
|
|
|
|
|
13.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Diluted EPS
|
|
$
|
0.44
|
|
|
$
|
(0.32
|
)
|
|
NA
|
|
|
$
|
0.39
|
|
|
13
|
%
|
Adjusted Diluted EPS*
|
|
$
|
0.57
|
|
|
$
|
0.46
|
|
|
24
|
%
|
|
$
|
0.56
|
|
|
2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA*
|
|
$
|
30,817
|
|
|
$
|
27,953
|
|
|
10
|
%
|
|
$
|
31,281
|
|
|
-1
|
%
|
Adjusted EBITDA as a % Sales
|
|
|
18.4
|
%
|
|
|
17.3
|
%
|
|
|
|
|
|
18.3
|
%
|
|
|
|
* Refer to Tables A, B and C at the end of this release for a
reconciliation of GAAP to adjusted amounts.
|
|
-
Sales increased to $167.7 million, reflecting 5% constant
currency organic growth over the comparable 2012 quarter.
-
Cardiac/neuromodulation revenue increased 8% driven by sustained
and deepening relations with OEM partners.
-
Orthopaedic revenue increased 11% over the prior year and 22%
after adjusting for the divestiture of certain non-core product
lines in Switzerland at the beginning of 2013 and foreign currency
exchange rate fluctuations. Share gains in both implants and cases
and trays generated the significant sales growth.
-
Electrochem revenue declined $1.9 million as a result of our
increased pricing discipline and reduced government funding on
military and environmental projects.
-
GAAP Operating Income of $17.0 million increased $14.9 million
versus the same period last year.
-
Gross margins improved 170 basis points to 33.3% driven by higher
volume and a better mix of product sales.
-
Total operating expenses declined $10.0 million or 20% as a result
of lower consolidation and optimization charges, partially offset
by higher selling and marketing investment and increased
performance based compensation.
-
Adjusted Operating Income improved 18% to $22.0 million and
increased 150 basis points to 13.1% of sales over the comparable 2012
quarter.
-
Gross profit improvement flowed through to adjusted operating
income.
CEO Comments
“The third quarter proved to be another solid performance from the team
with top line organic growth and operating leverage yielding an 18%
increase in adjusted operating income and a 24% improvement in adjusted
diluted EPS,” stated Thomas J. Hook, President and CEO, Greatbatch, Inc.
“Our sales and marketing investments and consolidation initiatives are
contributing to our revenue improvement and operating margin expansion.
For the fifth consecutive quarter, we have increased our adjusted
operating income and adjusted diluted EPS in comparison to the prior
year. We expect these initiatives to continue to pay dividends for the
remainder of 2013 and will position Greatbatch to meet its long-term
objective of maintaining at least 5% constant currency organic revenue
expansion and at least double that growth rate for adjusted diluted EPS
over time.”
CFO Comments
“For the fourth consecutive quarter our gross margins have improved in
comparison to the prior year and totaled 33.3% for the current quarter.
Most notably, increased operational leverage and a better sales mix, as
well as productivity enhancements from our Swiss consolidation and
business restructuring have led to our continued progress,” commented
Michael Dinkins, Executive Vice President & CFO, Greatbatch, Inc. “This
volume leverage, along with continued productivity, cost controls,
functional alignment and excellent execution also drove a 150 basis
point improvement in adjusted operating margins to 13.1% in the quarter.
Additionally, adjusted EBITDA improved 10%, which drove adjusted cash
flows from operations of $32.7 million for the quarter and $27.0 million
of debt repayment. Our third quarter results position us to be at the
lower end of our revenue guidance provided at the beginning of the year
and at the middle to upper end of our adjusted diluted EPS guidance,
which we raised last quarter.”
Third Quarter Results
Third quarter 2013 sales increased $6.4 million to $167.7 million. After
adjusting sales by $3.2 million for the divestiture of certain non-core
orthopaedic product lines during the first quarter of 2013 and
approximately $1 million for the positive impact of foreign currency
exchange rate fluctuations in comparison to the prior year, sales
increased $8.6 million or 5% organically. This growth was primarily due
to above market growth (8% growth) from our cardiac/neuromodulation
product line, as well as implant and cases and tray market share gains,
which helped drive 22% organic constant currency growth in our
orthopaedic product line. This growth was partially offset by a $1.4
million and $1.9 million decline in vascular and Electrochem sales,
respectively, due to the previously disclosed voluntary recall of two
vascular medical devices and continued pricing discipline in our
Electrochem product lines resulting in the loss of some low-margin
business. For the remainder of 2013, we expect revenue to remain strong
as new product introductions are commercialized, as we further partner
across business lines with our large OEM customers, and as we further
leverage our sales and marketing resources to drive core business growth.
Gross profit increased $4.9 million to $55.9 million in the third
quarter of 2013, compared to $51.0 million for the comparable 2012
period. This improvement was driven by increased operational leverage
due to our higher sales volumes, as well as a favorable mix of higher
margin products. As a result, gross profit as a percentage of sales for
the current quarter increased 170 basis points to 33.3% from 31.6% for
the prior year third quarter, representing the fourth consecutive
quarter our gross profit margin has increased in comparison to the prior
year.
Selling, general and administrative (“SG&A”) expenses increased $1.3
million to $21.6 million for the third quarter 2013 compared to $20.3
million for the same period of 2012. This increase is attributable to
the additional investments made in sales and marketing resources to
drive core business growth, as well as increased performance-based
compensation. Synergies realized from our Swiss orthopaedic facility
consolidation of approximately $0.4 million partially offset the rise in
expenses.
Net research, development and engineering (“RD&E”) costs for the 2013
third quarter of $13.8 million increased 4% over the $13.2 million
incurred during the third quarter of 2012. This increase was primarily
attributable to a decrease in customer cost reimbursements compared to
the prior year of $0.9 million, due to the timing of achievement of
milestones on various projects, as well as higher performance-based
compensation. These increases were partially offset by our initiative to
refocus our medical device RD&E investment, which began in the third
quarter of 2012, and included the discontinuation of certain non-core
projects. Current quarter results include $1.5 million of design
verification testing (“DVT”) costs incurred in connection with the
Company’s development of a neuromodulation platform compared to $1.2
million for the comparable 2012 period. In total, costs incurred in
connection with our medical device investments were $7.8 million in the
third quarter of 2013, compared to $8.7 million for the 2012 third
quarter. The Company’s medical device technology investment is focused
on successfully commercializing Algostim and being selective in
opportunities that leverage our strengths in our core business units and
drive sustainable growth.
GAAP operating income for the third quarter 2013 was $17.0 million
compared to $2.1 million for the comparable 2012 period. This increase
was primarily due to gross profit improvements and lower consolidation
and optimization costs ($11.2 million), partially offset by higher SG&A
and RD&E expenses. Adjusted operating income, which excludes other
operating and DVT expenses, increased 18% to $22.0 million compared to
$18.7 million in third quarter 2012. Refer to Table A at the end of this
release for a reconciliation of GAAP operating income to adjusted
operating income and the “Use of Non-GAAP Financial Information” section
below.
The GAAP effective tax rate for the first nine months of 2013 was 29.6%
compared to 93.0% for the same period of 2012. This decrease was
primarily attributable to $5.0 million of tax charges recorded during
the third quarter of 2012 in connection with our Swiss Orthopaedic
consolidation. These charges relate to the loss of our Swiss tax
holiday, due to our third quarter 2012 decision to discontinue
manufacturing in Switzerland and the valuation allowance established on
our Swiss deferred tax assets, as it was more likely than not that they
will not be fully realized. The reinstatement of the R&D tax credit in
2013, as well as higher income in lower tax rate jurisdictions also
contributed to the more favorable tax rate in 2013.
GAAP and adjusted diluted EPS for the third quarter of 2013 were $0.44
and $0.57, respectively, compared to a loss of $0.32 and income of
$0.46, respectively, for the third quarter 2012. Refer to Table B at the
end of this release for a reconciliation of GAAP net income (loss) to
adjusted net income and the “Use of Non-GAAP Financial Information”
section below.
Cash flow from operating activities for the third quarter of 2013 was
$24.7 million compared to $16.0 million in the 2012 period. This
increase was primarily due to a higher level of cash operating income.
During the third quarter of 2013, we made an $8.0 million estimated tax
payment related to the retirement of our convertible subordinated notes
in the first quarter of 2013. Excluding this tax payment, cash flow from
operations totaled $32.7 million for the third quarter of 2013. This
excess cash flow from operations was used to pay down $27.0 million of
long-term debt during the quarter. Additionally, during the third
quarter of 2013, we amended and extended our revolving credit facility
in order to extend the maturity date of this facility to 2018, take
advantage of favorable pricing and increase the total capacity of our
credit facility by $100 million.
Product Line Sales
The following table summarizes the Company’s sales by major product
lines (dollars in thousands):
|
|
Three Months Ended
|
|
|
September 27,
|
|
September 28,
|
|
%
|
|
June 28,
|
|
%
|
Product Line
|
|
2013
|
|
2012
|
|
Change
|
|
2013
|
|
Change
|
Implantable Medical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiac/Neuromodulation
|
|
$
|
86,980
|
|
$
|
80,246
|
|
8%
|
|
$
|
84,014
|
|
4%
|
Orthopaedic
|
|
|
30,079
|
|
|
27,173
|
|
11%
|
|
|
32,341
|
|
-7%
|
Vascular
|
|
|
12,279
|
|
|
13,674
|
|
-10%
|
|
|
12,249
|
|
0%
|
Total Implantable Medical
|
|
|
129,338
|
|
|
121,093
|
|
7%
|
|
|
128,604
|
|
1%
|
Electrochem
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Portable Medical
|
|
|
19,320
|
|
|
20,219
|
|
-4%
|
|
|
22,167
|
|
-13%
|
Energy
|
|
|
13,625
|
|
|
13,054
|
|
4%
|
|
|
13,107
|
|
4%
|
Other
|
|
|
5,447
|
|
|
6,974
|
|
-22%
|
|
|
7,453
|
|
-27%
|
Total Electrochem
|
|
|
38,392
|
|
|
40,247
|
|
-5%
|
|
|
42,727
|
|
-10%
|
Total Sales
|
|
$
|
167,730
|
|
$
|
161,340
|
|
4%
|
|
$
|
171,331
|
|
-2%
|
|
Implantable Medical
Cardiac and neuromodulation sales for the third quarter of 2013
increased 8% compared to the prior year to $87.0 million. This increase
was driven by stronger market performance and continued deepening
relationships with our OEM partners. More specifically, during the
quarter we experienced double digit growth in medical batteries,
capacitors, leads and feedthroughs. We continue to see an increased pace
of product development opportunities from our cardiac customers. We
believe that these opportunities, combined with our increased sales and
marketing resources, will allow the Company to continue to grow this
product line faster than the underlying market.
Orthopaedic sales of $30.1 million for the third quarter of 2013
increased 11% compared to the third quarter of 2012. During the first
quarter of 2013, the Company divested certain non-core orthopaedic
product lines, which reduced third quarter 2013 orthopaedic revenue by
approximately $3.2 million in comparison to the prior year period.
Additionally, foreign currency exchange rate fluctuations benefitted
current quarter orthopaedic revenue by approximately $1 million in
comparison to the prior year. On a constant currency organic basis,
orthopaedic product line sales increased 22% in comparison to the prior
year third quarter. This improvement was primarily due to orthopaedic
implant, and cases and tray market share gains, which benefitted from
our increased sales and marketing efforts to drive organic growth.
Third quarter 2013 vascular sales decreased $1.4 million to $12.3
million in comparison to the prior year period, reflecting the
previously communicated voluntary recall of two vascular medical devices
near the end of 2012.
Electrochem
Third quarter 2013 Electrochem sales decreased 5% to $38.4 million
compared to $40.2 million for the comparable 2012 period. During the
quarter, we experienced lower revenue from our portable medical,
environmental and military product lines, which are being impacted by
our increased pricing discipline, as well as reduced government funding
on certain military and environmental projects. We expect these factors
to continue to impact our business for the foreseeable future. Partially
offsetting these decreases was a 4% increase in our energy product line
as customer ordering patterns returned to normalized levels.
Financial Guidance
Based upon our results for the first three quarters, as well as our
expectations for the remainder of 2013, we continue to believe that
revenue will be at the lower end of our original sales guidance of $660
million to $680 million provided at the beginning of the year. If
achieved, this would result in organic revenue growth of 5% - 8% after
adjusting for the disposition of $15 million of non-core orthopaedic
product lines at the end of 2012. Because of our strong productivity
performance and favorable mix of product sales we believe that our
adjusted diluted EPS will be at the mid-point or better of our previous
$2.05 to $2.15 guidance. Further details will be provided on our
earnings call later today.
Conference Call
The Company will host a conference call on Thursday October 24, 2013 at
5:00 p.m. ET to discuss these results. The scheduled conference call
will be webcast live and is accessible through the Company’s website at www.greatbatch.com
or by dialing 866-318-8615 and entering pass code 22177520. An audio
replay will also be available beginning from 9:00 p.m. ET on October 24,
2013 until October 31, 2013. To access the replay, dial 888-286-8010
(U.S.) and enter the pass code 80216557.
About Greatbatch, Inc.
Greatbatch, Inc. (NYSE: GB) provides top-quality technologies to
industries that depend on reliable, long-lasting performance through its
brands Greatbatch Medical, Electrochem and QiG Group. Greatbatch Medical
develops and manufactures critical medical device technologies for the
cardiac, neuromodulation, vascular and orthopaedic markets. Electrochem
designs and manufactures batteries for high-end niche applications in
the portable medical, energy, military, and other markets. The QiG Group
empowers the design and development of new medical devices for our core
markets. Additional information about the Company is available at www.greatbatch.com.
Use of Non-GAAP Financial Information
In addition to our results reported in accordance with generally
accepted accounting principles (“GAAP”), we provide adjusted operating
income and margin, adjusted net income, adjusted earnings per diluted
share and adjusted EBITDA. These adjusted amounts, other than adjusted
EBITDA, consist of GAAP amounts excluding the following adjustments to
the extent occurring during the period: (i) acquisition-related charges,
(ii) facility consolidation, optimization, manufacturing transfer and
system integration charges, (iii) asset write-down and disposition
charges, (iv) severance charges in connection with corporate
realignments or a reduction in force (v) litigation charges and gains,
(vi) the impact of certain non-cash charges to interest expense, (vii)
unusual or infrequently occurring items, (viii) certain R&D expenditures
(such as medical device DVT expenses in connection with developing our
neuromodulation platform), (ix) gain/loss on the sale of investments,
(x) the income tax (benefit) related to these adjustments and (xi)
certain tax charges related to the consolidation of our Swiss
Orthopaedic facility. Adjusted earnings per diluted share were
calculated by dividing adjusted net income by diluted weighted average
shares outstanding. Adjusted EBITDA consists of adjusted operating
income excluding GAAP depreciation and amortization less adjustments
included in GAAP depreciation and amortization already excluded from
adjusted operating income. We believe that the presentation of adjusted
operating income and margin, adjusted net income, adjusted diluted
earnings per share and adjusted EBITDA provides important supplemental
information to management and investors seeking to understand the
financial and business trends relating to our financial condition and
results of operations.
Forward-Looking Statements
Some of the statements in this press release, including the information
provided under the caption “Financial Guidance,” are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of
1933, as amended, and section 21E of the Securities Exchange Act of
1934, as amended, and involve a number of risks and uncertainties. These
forward-looking statements can be identified by terminology such as
“may,” “will,” “should,” “could,” “expects,” “intends,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential,” or
“continue,” or variations or the negative of these terms or other
comparable terminology. These forward-looking statements are based on
the Company’s current expectations. The Company’s actual results could
differ materially from those stated or implied in such forward-looking
statements. Risks and uncertainties that could cause actual results to
differ materially from those stated or implied by such forward-looking
statements include, among others, the following matters affecting the
Company: our dependence upon a limited number of customers; customer
ordering patterns; product obsolescence; our inability to market current
or future products; pricing/vertical integration pressure from
customers; our ability to timely and successfully implement our cost
reduction and plant consolidation initiatives (including the
consolidation of our Swiss orthopaedic operations); our reliance on
third party suppliers for raw materials, products and subcomponents; our
inability to maintain high quality standards for our products;
challenges to our intellectual property rights; product liability
claims; our inability to successfully consummate and integrate
acquisitions and to realize synergies; our unsuccessful expansion into
new markets; our ability to realize a return on our substantial RD&E
investments, including system and device products; changes in and
challenges related to compliance with governmental laws and regulations,
including regulations of the U.S. Food and Drug Administration and
foreign government agencies regulating medical device approvals; our
inability to obtain licenses to key technology; regulatory changes or
consolidation in the healthcare industry; global economic factors
including currency exchange rates and interest rates; the resolution of
various legal actions and other risks and uncertainties described in the
Company’s Annual Report on Form 10-K and in other periodic filings with
the Securities and Exchange Commission. The Company assumes no
obligation to update forward-looking statements in this press release
whether to reflect changed assumptions, the occurrence of unanticipated
events or changes in future operating results, financial conditions or
prospects, or otherwise.
Table A: Operating Income Reconciliation:
|
|
|
|
Three Months Ended
|
|
|
Implantable Medical
|
|
Electrochem
|
|
Unallocated
|
|
Total
|
|
|
Sept. 27,
|
|
Sept. 28,
|
|
Sept. 27,
|
|
Sept. 28,
|
|
Sept. 27,
|
|
Sept. 28,
|
|
Sept. 27,
|
|
Sept. 28,
|
(dollars in thousands)
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
Sales
|
|
$
|
129,338
|
|
|
$
|
121,093
|
|
|
$
|
38,392
|
|
|
$
|
40,247
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
167,730
|
|
|
$
|
161,340
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) as reported
|
|
$
|
19,074
|
|
|
$
|
2,744
|
|
|
$
|
2,216
|
|
|
$
|
5,350
|
|
|
$
|
(4,288
|
)
|
|
$
|
(5,967
|
)
|
|
$
|
17,002
|
|
|
$
|
2,127
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical device DVT expenses (RD&E)
|
|
|
1,510
|
|
|
|
1,224
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,510
|
|
|
|
1,224
|
|
Consolidation and optimization costs
|
|
|
2,131
|
|
|
|
12,944
|
|
|
|
1,235
|
|
|
|
-
|
|
|
|
199
|
|
|
|
1,834
|
|
|
|
3,565
|
|
|
|
14,778
|
|
Acquisition and integration expenses (income)
|
|
|
(541
|
)
|
|
|
101
|
|
|
|
19
|
|
|
|
127
|
|
|
|
-
|
|
|
|
4
|
|
|
|
(522
|
)
|
|
|
232
|
|
Asset dispositions, severance and other
|
|
|
419
|
|
|
|
(129
|
)
|
|
|
38
|
|
|
|
432
|
|
|
|
-
|
|
|
|
-
|
|
|
|
457
|
|
|
|
303
|
|
Adjusted operating income (loss)
|
|
$
|
22,593
|
|
|
$
|
16,884
|
|
|
$
|
3,508
|
|
|
$
|
5,909
|
|
|
$
|
(4,089
|
)
|
|
$
|
(4,129
|
)
|
|
$
|
22,012
|
|
|
$
|
18,664
|
|
Adjusted operating margin
|
|
|
17.5
|
%
|
|
|
13.9
|
%
|
|
|
9.1
|
%
|
|
|
14.7
|
%
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
13.1
|
%
|
|
|
11.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical device related adjusted expenses (excluding DVT)
|
|
$
|
6,302
|
|
|
$
|
7,496
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
6,302
|
|
|
$
|
7,496
|
|
Adjusted operating income (loss) excluding medical device related
adjusted expenses
|
|
$
|
28,895
|
|
|
$
|
24,380
|
|
|
$
|
3,508
|
|
|
$
|
5,909
|
|
|
$
|
(4,089
|
)
|
|
$
|
(4,129
|
)
|
|
$
|
28,314
|
|
|
$
|
26,160
|
|
Adjusted operating margin excluding medical device related adjusted
expenses
|
|
|
22.3
|
%
|
|
|
20.1
|
%
|
|
|
9.1
|
%
|
|
|
14.7
|
%
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
16.9
|
%
|
|
|
16.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
|
|
|
Implantable Medical
|
|
Electrochem
|
|
Unallocated
|
|
Total
|
|
|
Sept. 27,
|
|
Sept. 28,
|
|
Sept. 27,
|
|
Sept. 28,
|
|
Sept. 27,
|
|
Sept. 28,
|
|
Sept. 27,
|
|
Sept. 28,
|
(dollars in thousands)
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
Sales
|
|
$
|
369,356
|
|
|
$
|
364,276
|
|
|
$
|
117,970
|
|
|
$
|
122,715
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
487,326
|
|
|
$
|
486,991
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) as reported
|
|
$
|
50,057
|
|
|
$
|
24,252
|
|
|
$
|
12,860
|
|
|
$
|
16,020
|
|
|
$
|
(14,441
|
)
|
|
$
|
(15,856
|
)
|
|
$
|
48,476
|
|
|
$
|
24,416
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory step-up amortization (COS)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
532
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
532
|
|
Medical device DVT expenses (RD&E)
|
|
|
4,479
|
|
|
|
3,839
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,479
|
|
|
|
3,839
|
|
Consolidation and optimization costs
|
|
|
7,956
|
|
|
|
16,407
|
|
|
|
1,361
|
|
|
|
-
|
|
|
|
1,018
|
|
|
|
4,394
|
|
|
|
10,335
|
|
|
|
20,801
|
|
Acquisition and integration expenses (income)
|
|
|
(430
|
)
|
|
|
245
|
|
|
|
89
|
|
|
|
1,037
|
|
|
|
1
|
|
|
|
5
|
|
|
|
(340
|
)
|
|
|
1,287
|
|
Asset dispositions, severance and other
|
|
|
472
|
|
|
|
378
|
|
|
|
93
|
|
|
|
843
|
|
|
|
-
|
|
|
|
672
|
|
|
|
565
|
|
|
|
1,893
|
|
Adjusted operating income (loss)
|
|
$
|
62,534
|
|
|
$
|
45,121
|
|
|
$
|
14,403
|
|
|
$
|
18,432
|
|
|
$
|
(13,422
|
)
|
|
$
|
(10,785
|
)
|
|
$
|
63,515
|
|
|
$
|
52,768
|
|
Adjusted operating margin
|
|
|
16.9
|
%
|
|
|
12.4
|
%
|
|
|
12.2
|
%
|
|
|
15.0
|
%
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
13.0
|
%
|
|
|
10.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical device related adjusted expenses (excluding DVT)
|
|
$
|
18,792
|
|
|
$
|
22,140
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
18,792
|
|
|
$
|
22,140
|
|
Adjusted operating income (loss) excluding medical device related
adjusted expenses
|
|
$
|
81,326
|
|
|
$
|
67,261
|
|
|
$
|
14,403
|
|
|
$
|
18,432
|
|
|
$
|
(13,422
|
)
|
|
$
|
(10,785
|
)
|
|
$
|
82,307
|
|
|
$
|
74,908
|
|
Adjusted operating margin excluding medical device related adjusted
expenses
|
|
|
22.0
|
%
|
|
|
18.5
|
%
|
|
|
12.2
|
%
|
|
|
15.0
|
%
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
16.9
|
%
|
|
|
15.4
|
%
|
|
Table B: Net Income (Loss) and Diluted EPS Reconciliation
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
September 27,
|
|
September 28,
|
|
September 27,
|
|
September 28,
|
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
(in thousands except per share amounts)
|
|
Net Income
|
|
Impact Per Diluted Share
|
|
Net Income
|
|
Impact Per Diluted Share
|
|
Net Income
|
|
Impact Per Diluted Share
|
|
Net Income
|
|
Impact Per Diluted Share
|
Net income (loss) as reported
|
|
$
|
11,071
|
|
|
$
|
0.44
|
|
|
$
|
(7,561
|
)
|
|
$
|
(0.32
|
)
|
|
$
|
26,486
|
|
|
$
|
1.06
|
|
|
$
|
757
|
|
|
$
|
0.03
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory step-up amortization (COS)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
346
|
|
|
|
0.01
|
|
Medical device DVT expenses (RD&E)
|
|
|
981
|
|
|
|
0.04
|
|
|
|
796
|
|
|
|
0.03
|
|
|
|
2,911
|
|
|
|
0.12
|
|
|
|
2,495
|
|
|
|
0.10
|
|
Consolidation and optimization costs(a)
|
|
|
2,453
|
|
|
|
0.10
|
|
|
|
11,119
|
|
|
|
0.46
|
|
|
|
7,749
|
|
|
|
0.31
|
|
|
|
15,034
|
|
|
|
0.63
|
|
Acquisition and integration expenses (income)(a)
|
|
|
(339
|
)
|
|
|
(0.01
|
)
|
|
|
151
|
|
|
|
0.01
|
|
|
|
(221
|
)
|
|
|
(0.01
|
)
|
|
|
837
|
|
|
|
0.03
|
|
Asset dispositions, severance and other(a)
|
|
|
298
|
|
|
|
0.01
|
|
|
|
197
|
|
|
|
0.01
|
|
|
|
389
|
|
|
|
0.02
|
|
|
|
1,230
|
|
|
|
0.05
|
|
Loss (gain) on cost and equity method investments, net(a)(b)
|
|
|
10
|
|
|
|
-
|
|
|
|
(228
|
)
|
|
|
(0.01
|
)
|
|
|
408
|
|
|
|
0.02
|
|
|
|
(228
|
)
|
|
|
(0.01
|
)
|
CSN conversion option discount and deferred fee accelerated
amortization(a)(c)
|
|
|
101
|
|
|
|
-
|
|
|
|
1,498
|
|
|
|
0.06
|
|
|
|
3,007
|
|
|
|
0.12
|
|
|
|
4,413
|
|
|
|
0.18
|
|
2012 R&D Tax Credit(d)
|
|
|
(100
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,600
|
)
|
|
|
(0.06
|
)
|
|
|
-
|
|
|
|
-
|
|
Swiss tax impact
|
|
|
-
|
|
|
|
-
|
|
|
|
5,008
|
|
|
|
0.21
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5,008
|
|
|
|
0.21
|
|
Adjusted net income and diluted EPS(e)
|
|
$
|
14,475
|
|
|
$
|
0.57
|
|
|
$
|
10,980
|
|
|
$
|
0.46
|
|
|
$
|
39,129
|
|
|
$
|
1.56
|
|
|
$
|
29,892
|
|
|
$
|
1.25
|
|
Adjusted diluted weighted average shares(f)
|
|
|
25,188
|
|
|
|
|
|
|
24,011
|
|
|
|
|
|
|
25,017
|
|
|
|
|
|
|
23,924
|
|
|
|
|
(a)
|
|
Net of tax amounts computed using a 35% U.S. statutory tax rate for
the 2013 and 2012 periods and a 0% and 22.5% Switzerland tax rate
for the 2013 and 2012 periods, respectively.
|
(b)
|
|
Pre-tax amounts are $16 thousand and $628 thousand for the 2013
quarter and year-to-date periods, respectively, and $350 thousand
for the 2012 quarter and year-to-date periods.
|
(c)
|
|
Pre-tax amounts are $156 thousand and $4.6 million for the 2013
quarter and year-to-date periods and $2.3 million and $6.8 million
for the 2012 quarter and year-to-date periods, respectively.
|
(d)
|
|
Relates to the 2012 portion of the R&D tax credit which was
reinstated in the first quarter of 2013 retroactive back to the
beginning of 2012. As required, the impact of the R&D tax credit
relating to 2012 was recognized in 2013.
|
(e)
|
|
The per share data in this table has been rounded to the nearest
$0.01 and therefore may not sum to the total.
|
(f)
|
|
Weighted average diluted shares for the third quarter of 2012
includes 365 thousand shares of dilution related to outstanding
stock incentive awards that were not dilutive for GAAP EPS purposes.
|
|
Table C: Adjusted EBITDA Reconciliation
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
September 27,
|
|
September 28,
|
|
September 27,
|
|
September 28,
|
(dollars in thousands)
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
Sales
|
|
$
|
167,730
|
|
|
$
|
161,340
|
|
|
$
|
487,326
|
|
|
$
|
486,991
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted operating income*
|
|
$
|
22,012
|
|
|
$
|
18,664
|
|
|
$
|
63,515
|
|
|
$
|
52,768
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add: Depreciation and amortization
|
|
|
8,805
|
|
|
|
11,966
|
|
|
|
26,658
|
|
|
|
34,070
|
|
Less adjustments included in depreciation and amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory step-up amortization
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(532
|
)
|
Consolidation and optimization accelerated depreciation
|
|
|
-
|
|
|
|
(2,677
|
)
|
|
|
-
|
|
|
|
(4,469
|
)
|
Adjusted EBITDA
|
|
$
|
30,817
|
|
|
$
|
27,953
|
|
|
$
|
90,173
|
|
|
$
|
81,837
|
|
Adjusted EBITDA as a % of sales
|
|
|
18.4
|
%
|
|
|
17.3
|
%
|
|
|
18.5
|
%
|
|
|
16.8
|
%
|
|
* Refer to table A for a reconciliation of GAAP to adjusted amounts.
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - Unaudited
|
(in thousands except per share data)
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
September 27,
|
|
September 28,
|
|
September 27,
|
|
September 28,
|
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales
|
|
$
|
167,730
|
|
|
$
|
161,340
|
|
|
$
|
487,326
|
|
|
$
|
486,991
|
|
Cost of sales
|
|
|
111,853
|
|
|
|
110,386
|
|
|
|
325,398
|
|
|
|
337,216
|
|
Gross profit
|
|
|
55,877
|
|
|
|
50,954
|
|
|
|
161,928
|
|
|
|
149,775
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
21,569
|
|
|
|
20,274
|
|
|
|
63,909
|
|
|
|
60,053
|
|
Research, development and engineering costs, net
|
|
|
13,806
|
|
|
|
13,240
|
|
|
|
38,983
|
|
|
|
41,325
|
|
Other operating expenses, net
|
|
|
3,500
|
|
|
|
15,313
|
|
|
|
10,560
|
|
|
|
23,981
|
|
Total operating expenses
|
|
|
38,875
|
|
|
|
48,827
|
|
|
|
113,452
|
|
|
|
125,359
|
|
Operating income
|
|
|
17,002
|
|
|
|
2,127
|
|
|
|
48,476
|
|
|
|
24,416
|
|
Interest expense
|
|
|
1,515
|
|
|
|
4,401
|
|
|
|
9,948
|
|
|
|
13,175
|
|
Other (income) expense, net
|
|
|
(57
|
)
|
|
|
(102
|
)
|
|
|
907
|
|
|
|
424
|
|
Income (loss) before provision for income taxes
|
|
|
15,544
|
|
|
|
(2,172
|
)
|
|
|
37,621
|
|
|
|
10,817
|
|
Provision for income taxes
|
|
|
4,473
|
|
|
|
5,389
|
|
|
|
11,135
|
|
|
|
10,060
|
|
Net income (loss)
|
|
$
|
11,071
|
|
|
$
|
(7,561
|
)
|
|
$
|
26,486
|
|
|
$
|
757
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.46
|
|
|
$
|
(0.32
|
)
|
|
$
|
1.11
|
|
|
$
|
0.03
|
|
Diluted
|
|
$
|
0.44
|
|
|
$
|
(0.32
|
)
|
|
$
|
1.06
|
|
|
$
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
24,047
|
|
|
|
23,646
|
|
|
|
23,904
|
|
|
|
23,559
|
|
Diluted
|
|
|
25,188
|
|
|
|
23,646
|
|
|
|
25,017
|
|
|
|
23,924
|
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS - Unaudited
|
(in thousands)
|
|
|
|
As of
|
ASSETS
|
|
September 27,
|
|
December 28,
|
|
2013
|
|
2012
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
4,973
|
|
|
$
|
20,284
|
|
Accounts receivable, net
|
|
|
130,966
|
|
|
|
120,923
|
|
Inventories
|
|
|
122,823
|
|
|
|
106,612
|
|
Refundable income taxes
|
|
|
566
|
|
|
|
-
|
|
Deferred income taxes
|
|
|
8,077
|
|
|
|
7,678
|
|
Prepaid expenses and other current assets
|
|
|
8,028
|
|
|
|
12,636
|
|
Total current assets
|
|
|
275,433
|
|
|
|
268,133
|
|
Property, plant and equipment, net
|
|
|
147,431
|
|
|
|
150,893
|
|
Amortizing intangible assets, net
|
|
|
77,518
|
|
|
|
87,345
|
|
Indefinite-lived intangible assets
|
|
|
20,402
|
|
|
|
20,828
|
|
Goodwill
|
|
|
346,614
|
|
|
|
349,035
|
|
Deferred income taxes
|
|
|
2,762
|
|
|
|
2,534
|
|
Other assets
|
|
|
14,551
|
|
|
|
11,107
|
|
Total assets
|
|
$
|
884,711
|
|
|
$
|
889,875
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Accounts payable
|
|
$
|
36,478
|
|
|
$
|
45,274
|
|
Income taxes payable
|
|
|
11,177
|
|
|
|
94
|
|
Deferred income taxes
|
|
|
881
|
|
|
|
874
|
|
Accrued expenses
|
|
|
43,207
|
|
|
|
45,515
|
|
Total current liabilities
|
|
|
91,743
|
|
|
|
91,757
|
|
Long-term debt
|
|
|
210,000
|
|
|
|
225,414
|
|
Deferred income taxes
|
|
|
51,732
|
|
|
|
82,462
|
|
Other long-term liabilities
|
|
|
6,779
|
|
|
|
9,382
|
|
Total liabilities
|
|
|
360,254
|
|
|
|
409,015
|
|
Stockholders’ equity:
|
|
|
|
|
|
Preferred stock
|
|
|
-
|
|
|
|
-
|
|
Common stock
|
|
|
24
|
|
|
|
24
|
|
Additional paid-in capital
|
336,491
|
|
|
|
320,618
|
|
Treasury stock
|
|
|
(593
|
)
|
|
|
(452
|
)
|
Retained earnings
|
|
|
174,209
|
|
|
|
147,723
|
|
Accumulated other comprehensive income
|
|
|
14,326
|
|
|
|
12,947
|
|
Total stockholders’ equity
|
|
|
524,457
|
|
|
|
480,860
|
|
Total liabilities and stockholders’ equity
|
|
$
|
884,711
|
|
|
$
|
889,875
|
|
Source: Greatbatch, Inc.
Greatbatch, Inc.
Betsy Cowell, 214-618-4982
VP Finance and
Treasurer
ecowell@greatbatch.com